Tower Research Capital LLC (Trc) Xenon Pharmaceuticals Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 647 shares of XENE stock, worth $25,705. This represents 0.0% of its overall portfolio holdings.
Number of Shares
647
Previous 2,019
67.95%
Holding current value
$25,705
Previous $79,000
68.35%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
70.4MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$225 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$180 Million1.73% of portfolio
-
Wellington Management Group LLP Boston, MA3.78MShares$150 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$116 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$114 Million0.06% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.47B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...